194 related articles for article (PubMed ID: 21477348)
1. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
[TBL] [Abstract][Full Text] [Related]
2. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
4. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Kanakry CG; Tsai HL; Bolaños-Meade J; Smith BD; Gojo I; Kanakry JA; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Powell JD; Pratz KW; DeZern AE; Showel MM; McDevitt MA; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Blood; 2014 Dec; 124(25):3817-27. PubMed ID: 25316679
[TBL] [Abstract][Full Text] [Related]
5. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
6. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
[TBL] [Abstract][Full Text] [Related]
7. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
Guru Murthy GS; Logan BR; Bo-Subait S; Beitinjaneh A; Devine S; Farhadfar N; Gowda L; Hashmi S; Lazarus H; Nathan S; Sharma A; Yared JA; Stefanski HE; Pulsipher MA; Hsu JW; Switzer GE; Panch SR; Shaw BE
Am J Hematol; 2023 Apr; 98(4):608-619. PubMed ID: 36606713
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Ciurea SO; Shah MV; Saliba RM; Gaballa S; Kongtim P; Rondon G; Chen J; Wallis W; Cao K; Konopleva M; Daver N; Cortes J; Ravandi F; Alousi A; Ahmed S; Popat U; Parmar S; Bashir Q; Betul O; Hosing C; Shpall EJ; Rezvani K; Khouri IF; Kebriaei P; Champlin RE
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1232-1236. PubMed ID: 28918304
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
10. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades.
Ohbiki M; Ito Y; Inamoto Y; Miyamura K; Uchida N; Fukuda T; Fujiwara H; Nishida T; Hayashi M; Tanaka M; Kawakita T; Ikegame K; Katayama Y; Ara T; Ichinohe T; Kiyoi H; Matsuo K; Atsuta Y
Transplant Cell Ther; 2023 Dec; 29(12):768.e1-768.e10. PubMed ID: 37739224
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic analysis of patients with acute leukemia and central nervous system involvement undergoing allogeneic hematopoietic stem cell transplantation].
Liu J; Ma R; He Y; Luo XY; Han W; Han TT; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Nov; 62(11):1295-1302. PubMed ID: 37935495
[No Abstract] [Full Text] [Related]
12. Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.
Avenoso D; Mehra V; Slonim LB; de Farias M; Alshehri H; Bouziana S; Krishnamurthy P; Kulasekararaj A; Dazzi F; Wood H; Kenyon M; Leung YT; Anteh S; Shah MN; Hannah G; Serpenti F; Gameil A; Bourlon C; Dragoi OD; Pagliuca A; Potter V
Transplant Cell Ther; 2023 Nov; 29(11):698.e1-698.e6. PubMed ID: 37579918
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
14. No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
Gadalla SM; Wang T; Loftus D; Friedman L; Dagnall C; Haagenson M; Spellman SR; Buturovic L; Blauwkamp M; Shelton J; Fleischhauer K; Hsu KC; Verneris MR; Krstajic D; Hicks B; Jones K; Lee SJ; Savage SA
Bone Marrow Transplant; 2018 Apr; 53(4):383-391. PubMed ID: 29269807
[TBL] [Abstract][Full Text] [Related]
15. Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement.
Takahashi T; Lake AJ; Wachter F; Calderon FA; Dandoy C; Keating AK
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38763417
[TBL] [Abstract][Full Text] [Related]
16. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
[No Abstract] [Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Platzbecker U; Schetelig J; Finke J; Trenschel R; Scott BL; Kobbe G; Schaefer-Eckart K; Bornhäuser M; Itzykson R; Germing U; Beelen D; Ehninger G; Fenaux P; Deeg HJ; Adès L; ; ; ;
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1415-21. PubMed ID: 22579634
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
Davies JK; Taussig D; Oakervee H; Smith M; Agrawal S; Cavenagh JD; Gribben JG
Br J Haematol; 2013 Aug; 162(4):525-9. PubMed ID: 23718277
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T; Stelljes M; Christopeit M; Esseling E; Scheid C; Mikesch JH; Rautenberg C; Jäger P; Cadeddu RP; Drusenheimer N; Holtick U; Klein S; Trenschel R; Haas R; Germing U; Kröger N; Kobbe G
Haematologica; 2023 Nov; 108(11):3001-3010. PubMed ID: 37259567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
